Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Redsense Medical AB's Net Cash per Share or its related term are showing as below:
RDSNF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.57 Med: 28 Max: 292.22
Current: 25.5
During the past 13 years, the highest Price-to-Net-Cash Ratio of Redsense Medical AB was 292.22. The lowest was 7.57. And the median was 28.00.
RDSNF's Price-to-Net-Cash is ranked worse than 78.91% of 294
companies
in the Medical Devices & Instruments industry
Industry Median: 9.35
vs RDSNF: 25.50
Redsense Medical AB (OTCPK:RDSNF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Redsense Medical AB Net Cash per Share Related Terms
Redsense Medical AB Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Redsense Medical AB's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDSNF vs ABT, SYK, MDT: Net Cash per Share Comparison
For the Medical Devices subindustry, Redsense Medical AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redsense Medical AB Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Redsense Medical AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Redsense Medical AB's Price-to-Net-Cash falls into.
Redsense Medical AB Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Redsense Medical AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Redsense Medical AB (RDSNF) has a Net Cash per Share of $0.01 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Redsense Medical AB and its competitors. According to the industry distribution chart, Redsense Medical AB ranks #232 out of 294 companies in the Medical Devices & Instruments industry, placing it in the top 78.9%.
Is Redsense Medical AB's Net Cash per Share too high?
Redsense Medical AB's current Net Cash per Share is $0.01. The Medical Devices & Instruments industry median Net Cash per Share is 9.35. Redsense Medical AB's value of $0.01 is 99.9% below this industry median. Based on the distribution chart, Redsense Medical AB ranks #232 out of 294 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Redsense Medical AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Redsense Medical AB's Net Cash per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Redsense Medical AB ranks #232 out of 294 companies for Net Cash per Share. This places Redsense Medical AB in the lower half of its industry. The industry median Net Cash per Share is 9.35. Redsense Medical AB's value of $0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.35, based on 294 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Redsense Medical AB's current Net Cash per Share of $0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Redsense Medical AB and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redsense Medical AB's current Net Cash per Share is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redsense Medical AB stock overvalued right now?
Redsense Medical AB (RDSNF) has a current Net Cash per Share of $0.01. The stock's GF Value™ is $0.99, compared to a current price of $0.51 — trading 48.5% below its estimated fair value. The current Net Cash per Share is $0.01 and 99.9% below the Medical Devices & Instruments industry median of 9.35. Redsense Medical AB's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Redsense Medical AB (RDSNF), the current Net Cash per Share is $0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Redsense Medical AB (RDSNF) Overvalued in 2026?
Based on GuruFocus' analysis, Redsense Medical AB stock appears to be undervalued.
The current stock price of $0.51 is trading 48.5% below its estimated GF Value™ of $0.99.
Key valuation signals for RDSNF:
Net Cash per Share: $0.01
GF Value™: $0.99 vs. price of $0.51 (48.5% below fair value)
Industry Position: 99.9% below the Medical Devices & Instruments median (#232 of 294)
No single metric tells the full story. See the RDSNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Redsense Medical AB manufactures and sells blood loss detection devices in Sweden. The company has developed a monitoring system that can detect the first sign of a blood leak using patented fiber optic technology. The products of the company include Alarm Unit, Venous Needle Patch, Sensor Patch, and others.
59GF Score
Get the complete analysis for RDSNF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDSNF has been successfully added to your 
